Four orphan drugs, three biosimilars, and one monoclonal antibody therapy have been recommended for EU market...
Up To Date
Latest News
With treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now,...
Synthetic promoter and gene expression specialist Synpromics has completed a £5.2m (€6.2m) financing round...
Autoimmune specialist Galapagos NV (Mechelen, Belgium) has priced its 3,750,000 American Depository Shares...
Irish Allergan and Swiss Novartis have agreed to start a proof-of-concept study of a combination of their NASH...
sphingotec GmbH and bestbion dx GmbH have signed an agreement to market sphingotec’s innovative sepsis and...